|
COPYRIGHT 2007 FT Business
"We've achieved what we set out to achieve," says Cobra's executive chairman Peter Fothergill, having announced a return to profitability after a tough two years. The biopharmaceutical manufacturer had a turbulent time after the bottom fell out of the plasmid DNA market and biotech customers in Europe struggled to...
Read the full article for free courtesy of your local library.
|